Adial Pharmaceuticals, Inc. (ADIL) Stock Analysis & Investment Frameworks
Adial Pharmaceuticals, Inc. (ADIL) stock analysis on Invetso. Review Adial Pharmaceuticals, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Adial Pharmaceuticals, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Adial Pharmaceuticals, Inc. Key Financial Metrics
- Market Cap: $10.29M
- Revenue: $N/A
- ROE: -1693.21%
- ROIC: -240.64%
- Dividend Yield: N/A
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
Adial Pharmaceuticals, Inc. Investment Frameworks
Invetso analyzes Adial Pharmaceuticals, Inc. (ADIL) across the following frameworks:
- Adial Pharmaceuticals, Inc. 10Y Growth Potential
- Adial Pharmaceuticals, Inc. Scenario Analysis
- Adial Pharmaceuticals, Inc. Risks & Opportunities
- Adial Pharmaceuticals, Inc. Economic Moat
- Adial Pharmaceuticals, Inc. Business Model
- Adial Pharmaceuticals, Inc. Management
- Adial Pharmaceuticals, Inc. SWOT Analysis
- Adial Pharmaceuticals, Inc. Porter's 5 Forces
- Adial Pharmaceuticals, Inc. PESTLE Analysis
- Adial Pharmaceuticals, Inc. ESG Analysis